LONG MINI-FUTURE - GENMAB | Market Closed - Börse Stuttgart 07:52:05 24/05/2024 BST | ||
| 14.3 EUR | -3.83% |
|
| Current month | +0.21% | ||
| 1 month | +1.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 14.3 | -3.83% |
| 23/05/24 | 14.87 | +6.37% |
| 22/05/24 | 13.98 | -3.92% |
| 21/05/24 | 14.55 | -0.07% |
| 17/05/24 | 14.56 | -2.41% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 07:52 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VA8XDF |
| ISIN | DE000VA8XDF0 |
| Date issued | 26/10/2018 |
| Strike | 935.8 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.59 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 32.98 € |
|---|---|
| Lowest since issue | 0.95 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,926
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.99%
- Stock Market
- Certificates
- Certificat
